ICT19G1 Receives IND Approval for Treatment of Relapsed/Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia

Recently, Shanghai Si Dan Race BioTechnology Co., Ltd., located in Zhangjiang Science City, has obtained clinical trial approval for its Class 1 new biological drug for therapeutic use, ICT19G1 (Acceptance No.: CXSL1800020). This product is indicated for the treatment of adult patients with relapsed or refractory CD19-positive B-cell lineage acute lymphoblastic leukemia.

ICT R&D Pipeline Source: ICT Official Website